

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**March 18, 2025**

---

**I Continuing Review**

**10005**, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma (Version Date 04/19/24)

---

**II Continuing Review**

**10301**, A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Version Date 08/07/24)

---

**III Continuing Review**

**10100**, A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option (Version Date 10/05/23)

---